Deyaa Adib, M.D., Chief Medical Officer, joined AffyImmune in November 2024. Dr. Adib has over 28 years of experience in the biotechnology and pharmaceutical industries in multidisciplinary oncology and immuno-oncology from drug research, through commercialization experience with 7 global registrations including Taxotere, Eloxatin, Xtandi, Oncaspar, Maverick, Oomycide and Eclosing in multiple indications across hematologic malignancies and solid tumors. Prior to joining AffyImmune, he was the Chief Medical Officer of  FibroGen and previously the CMO for Triumvira Immunologics. He served as Acting CMO at Rain Therapeutics advancing the organization from the private into public sector via a successful IPO.

Before that, he was the Vice President of late-stage development at Blueprint Medicines. Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals repositioning ponatinib from local into global domain. Earlier in his career, he held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma. Dr. Adib obtained an M.B., B.Ch. degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation. He completed his research fellowship in cancer immunology and rheumatology at St. Joseph’s Hospital & Medical Center in Paterson, New Jersey.

Sonal brings more than 15 years of industry experience, including leadership roles at AVROBIO, CRISPR Therapeutics and Rubius Therapeutics. She has built and led translational research and medicine teams across multiple therapeutic areas, including oncology and rare diseases. In addition, Sonal’s specialties include clinical trial design and execution, medical monitoring, and clinical data management and interpretation, including biomarker strategies. Sonal earned her PhD in cancer research from the University of Bradford in the UK, and her medical degree from the Government Medical College, Surat in India.

Pete brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune. Previously, he served as the Head of Manufacturing and Technical Operations at ElevateBio, where he led Technology Transfer, CMC strategy, and oversight of routine clinical manufacturing. During his tenure at bluebird bio, he led both the MSAT and CMC teams for Skysona. He has executed numerous late-phase global technology transfer deals and played a pivotal role in driving the drug product process validation efforts for Zynteglo. Peter has also held various positions at the Connell O’Reilly Cell Manipulation Core Facility (CMCF) at Dana Farber Cancer Institute (DFCI), where he contributed to the development and manufacturing of several gene and cell-based therapies.

Dawn is a seasoned Clinical Operations leader, with over 25 years of industry experience. Her career has held a focus in early development oncology at both large and small pharma. Prior to joining AffyImmune, Dawn led the entire early development Cell Therapy portfolio for clinical trials at BMS. Her tenure at BMS/Celgene includes 5 years in Cell Therapy in both Clinical Operations and Manufacturing roles. She received a B.S. in Business and Marketing from Skidmore College and holds APMP qualification from the Association for Project Management.

Arya has twenty-five years of experience at building and leading Process Development, Global Manufacturing, and Global Quality organizations at companies including Novartis, Biogen, Alnylam, and Invivyd. He has contributed to the development and commercialization of eight new drugs across multiple therapeutic areas including auto-immune, genetic, oncology, and infectious disease indications. Arya received his B.S. in Chemical Engineering from the University of California – Berkely and his Ph.D. in Chemical Engineering and Pharmaceutical Sciences from the University of Arizona.

Josh brings 10 years of accounting and finance experience to AffyImmune, including 4 years of increasing responsibility at Affy. Josh joined Affy from Deloitte, where he worked with technology and biotechnology clients in the firm’s audit practice. Recently, he has served as an advisor to SaaS, civic-tech, and biotechnology startups with a focus on innovative technology and as a nonprofit Board member. Josh received his B.S. degree from Babson College and is a Certified Public Accountant in Massachusetts.